EFFECTS OF FOLIC ACID AND VITAMIN B12 SUPPLEMENTATION ON NEGATIVE SYMPTOMS AND RELATED MRI INDICES

2014 ◽  
Vol 153 ◽  
pp. S80 ◽  
Author(s):  
Joshua Roffman ◽  
Steven J. Lamberti ◽  
Eric Achtyes ◽  
Eric A. Macklin ◽  
Gail C. Galendez ◽  
...  
2020 ◽  
Vol 16 (1) ◽  
pp. 98-104
Author(s):  
Rona Hanani Simamora ◽  
Bahagia Loebis ◽  
Muhammad Surya Husada ◽  
Elmeida Effendy

Background: Schizophrenia is a chronic mental disorder that affects approximately 1% of the world’s population. Particularly, negative symptoms are frequently resistant and are the main contributors to the disability on schizophrenia patients. Folic acid and vitamin B12 supplementation is the safe and affordable approach, which can significantly improve the outcome on the patients with residual symptoms. Objectives: We aimed to understand the difference of negative subscale of Positive and Negative Syndrome Scale (PANSS) Score on patients with schizophrenia who receive risperidone with the addition folic acid and Vitamin B12 and patients who receive only risperidone after 6 weeks. Methods: This study is a quasi experimental pre-test and post-test designs that are divided into two groups, they are group receiving risperidone with the addition of folic acid and vitamin B12 and the group receiving only risperidone. Diagnosis of schizophrenia according to the International Classification of Diseases (ICD-10) criteria and negative symptoms assessed by using negative subscale of PANSS Scores are observed. Statistical analysis is conducted using Statistical Package for the Social Sciences (SPSS) software. Results: There was a significant difference in the mean score of negative-scale PANSS scores at the end of week 6 between the group receiving folic acid and vitamin B12 supplementation and the group receiving only risperidone with p = 0.002; p <0.05. Conclusion: Folic acid and vitamin B12 Supplementation provide benefits to patients schizophrenia.


2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Sadaf Oliai Araghi ◽  
Jessica C Kiefte-de Jong ◽  
Suzanne van Dijk ◽  
Natasja van Schoor ◽  
Lisette CPGM de Groot ◽  
...  

Abstract Objectives To investigate the possible effects of the intervention with folic acid and vitamin B12 supplementation on fracture and cardiovascular disease risk: 5–7 years after the end of the intervention period of 2–3 years. Methods Extended follow-up of B-PROOF trial, a multi-center, double-blind randomized placebo-controlled trial designed to assess the effect of 2–3 years daily supplementation with folic acid (400 µg) and vitamin-B12 (500 µg) versus placebo on fracture incidence. Fracture and cardiovascular outcomes were assessed by follow-up questionnaire. Fracture incidence (and a part of cardiovascular disease incidence) was verified by general practitioners (GPs). Results A total of 1298 individuals participated in the second follow-up round. Median age at baseline was 71.0 years [68.0–76.0] for both groups (n = 662 in the treatment group and n = 636 in the placebo group). No effect of the intervention on first osteoporotic fracture and other fracture risk after a follow up of 5–7 years was observed (HR: 0.99, 95% CI: 0.62; 1.59 and HR: 0.77; 95% CI: 0.50; 1.19, respectively) and also not for cardiovascular- or cerebrovascular disease (OR: 1.14; 95%CI: 0.74–1.74 and OR: 1.01; 95%CI: 0.76–1.33, respectively). Significant interaction for total homocysteine level was observed for osteoporotic- and any fracture (P = 0.10 and 0.06 resp.), which indicated a significantly lower risk of fracture in the intervention group with higher total homocysteine level. Conclusions This study does not support a prolonged effect of supplementation of folic acid and vitamin B12 on fracture risk, or on cardiovascular disease in older individuals with elevated homocysteine concentration. However, B-vitamin supplementation may be beneficial in reducing fractures in individuals with higher total homocysteine levels. Funding Sources The initial B-PROOF study has received funding so far by The Netherlands Organization for Health Research and Development (ZonMw), the Hague; unrestricted grant from NZO (Dutch Dairy Association), Zoetermeer; Orthica, Almere; NCHA (Netherlands Consortium Healthy Ageing) Leiden/Rotterdam; Ministry of Economic Affairs, Agriculture and Innovationn, the Hague; Wageningen University, Wageningen; VUmc, Amsterdam; Erasmus Medical Center, Rotterdam. Supporting Tables, Images and/or Graphs


Author(s):  
Sadaf Oliai Araghi ◽  
Jessica C. Kiefte-de Jong ◽  
Suzanne C. van Dijk ◽  
Karin M.A. Swart ◽  
Kim J. Ploegmakers ◽  
...  

2012 ◽  
Vol 87 (Suppl_1) ◽  
pp. 504-504 ◽  
Author(s):  
Annie Gagnon ◽  
Marc-André Sirard ◽  
François Richard ◽  
Jean-Paul Laforest

2014 ◽  
Vol 97 (4) ◽  
pp. 2346-2354 ◽  
Author(s):  
M. Duplessis ◽  
C.L. Girard ◽  
D.E. Santschi ◽  
J.-P. Laforest ◽  
J. Durocher ◽  
...  

2019 ◽  
Vol 16 (7) ◽  
pp. 622-632 ◽  
Author(s):  
Fei Ma ◽  
Xuan Zhou ◽  
Qing Li ◽  
Jiangang Zhao ◽  
Aili Song ◽  
...  

Background: Folate and vitamin B12 are well-known as essential nutrients that play key roles in the normal functions of the brain. Inflammatory processes play at least some role in the pathology of AD. Effective nutritional intervention approaches for improving cognitive deficits that reduce the peripheral inflammatory cytokine levels have garnered special attention. Objective: The present study aimed to determine whether supplementation with folic acid and vitamin B12, alone and in combination improves cognitive performance via reducing levels of peripheral inflammatory cytokines. Methods: 240 participants with MCI were randomly assigned in equal proportion to four treatment groups: folic acid alone, vitamin B12 alone, folic acid plus vitamin B12 or control without treatment daily for 6 months. Cognition was measured with WAIS-RC. The levels of inflammatory cytokines were measured using ELISA. Changes in cognitive function or blood biomarkers were analyzed by repeatedmeasure analysis of variance or mixed-effects models. This trial has been registered with trial number ChiCTR-ROC-16008305. Results: Compared with control group, the folic acid plus vitamin B12 group had significantly greater improvements in serum folate, homocysteine, vitamin B12 and IL-6, TNF-α, MCP-1. The folic acid plus vitamin B12 supplementation significantly changed the Full Scale IQ (effect size d = 0.169; P = 0.024), verbal IQ (effect size d = 0.146; P = 0.033), Information (d = 0.172; P = 0.019) and Digit Span (d = 0.187; P = 0.009) scores. Post hoc Turkey tests found that folic acid and vitamin B12 supplementation was significantly more effective than folic acid alone for all endpoints. Conclusions: The combination of oral folic acid plus vitamin B12 in MCI elderly for six months can significantly improve cognitive performance and reduce the levels of inflammatory cytokines in human peripheral blood. The combination of folic acid and vitamin B12 was significantly superior to either folic acid or vitamin B12 alone.


2008 ◽  
Vol 23 (10) ◽  
pp. 3272-3279 ◽  
Author(s):  
H. Stopper ◽  
A.-T. Treutlein ◽  
U. Bahner ◽  
N. Schupp ◽  
U. Schmid ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document